TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2021123

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% of calories as fat)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control diet (35-40% fat)
Number of subjects: 13
Study: 7056952

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) at 1600 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) used well in excess of its presumed therapeutic dose range
Number of subjects: 0
Study: 31829910

Group type: EXPERIMENTAL
Intervention: PVP with a 940-nm diode laser
Number of subjects: 126
Study: 28869198

Group type: EXPERIMENTAL
Intervention: Stereotactic body irradiation to all macroscopic metastatic sites and the primary disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26096714

Group type: EXPERIMENTAL
Intervention: Integrated Coaching for Better Mood and Weight (I‐CARE) program
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care enhanced with the provision of a pedometer and information about the health system's services for mood or weight management
Number of subjects: 404
Study: 24461067

Group type: EXPERIMENTAL
Intervention: Proficiency-based training in the LapSimGyn(®) virtual reality simulator
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Additional structured mentorship during subsequent laparoscopies
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 28
Study: 20827794

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 19191674

Group type: EXPERIMENTAL
Intervention: T80/H25 fixed-dose combination (FDC)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: T80/H25 fixed-dose combination (FDC) with additional antihypertensive medication
Number of subjects: 639
Study: 17121197

Group type: EXPERIMENTAL
Intervention: Moisture Insensitive Primer (MIP) on enamel etched and dry
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Moisture Insensitive Primer (MIP) on saliva-wet enamel
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: One Step Self Etching Primer (SEP) on dry field
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: One Step Self Etching Primer (SEP) on saliva-wet enamel
Number of subjects: 124
Study: 14701777

Group type: EXPERIMENTAL
Intervention: IDA/IDA
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: IDA/DNR
Number of subjects: 93

Group type: COMPARATOR
Intervention: DNR/DNR
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CCG‐2941
Number of subjects: 93
Study: 11744584

Group type: COMPARATOR
Intervention: mivacurium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 60
Study: 9296409

Group type: COMPARATOR
Intervention: 3 ml 0.17% bupivacaine in 2.66% dextrose without fentanyl (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 ml 0.17% bupivacaine in 2.66% dextrose with 10 microg fentanyl (Group II)
Number of subjects: 50
Study: 8488993

Group type: EXPERIMENTAL
Intervention: Acupressure (small metal bullets fastened at point P 6 on each forearm for 24 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (no specific intervention mentioned)
Number of subjects: 60
Study: 3511689

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60
Study: 29752026

Group type: EXPERIMENTAL
Intervention: RotaSIIL
Number of subjects: 4092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4092
Study: 27642130

Group type: EXPERIMENTAL
Intervention: GEN-003 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigens without adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25133840

Group type: EXPERIMENTAL
Intervention: PA-promoting message
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy eating message
Number of subjects: 101
Study: 23392542

Group type: EXPERIMENTAL
Intervention: B6 (250 mg/day) for five months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: B1+B6 (250 mg/day each) for five months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diabetic group with nephropathy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diabetic group without nephropathy
Number of subjects: 57
Study: 21334555

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 110
Study: 18493261

Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (video adventures and rewards for eating fruit and vegetables)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (parental provision and children's consumption of lunchbox fruit, vegetables, and juice)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 435
Study: 17459783

Group type: EXPERIMENTAL
Intervention: FDG‐PET based diagnostic arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional diagnostic arm (direct laryngoscopy for all patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study: 15327042

Group type: EXPERIMENTAL
Intervention: Cannabis-based medicinal extract (CBME)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 11350461

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.75 MAC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.0 MAC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane 1.25 MAC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.75 MAC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.25 MAC
Number of subjects: 40
Study: 9164897

Group type: EXPERIMENTAL
Intervention: sustained-release verapamil
Number of subjects: 13
Study: 7695185

Group type: EXPERIMENTAL
Intervention: Combined drug therapy to prevent restenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local delivery of drug at the site of injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of highly specific drugs including local gene therapy
Number of subjects: 0
Study: 2687007

Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Miglitol 75 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Miglitol 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 8
Study: 334608

Group type: EXPERIMENTAL
Intervention: Butacote (enteric-coated phenylbutazone) 300 mg daily
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 31576471

Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 31030296

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC; 20 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 29282015

Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 843
Study: 25612795

Group type: EXPERIMENTAL
Intervention: Nurse-led psychosocial intervention (NUCAI)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 205
Study: 25715322

Group type: EXPERIMENTAL
Intervention: Parent binge eating symptoms
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Parent depressive symptoms
Number of subjects: 77
Study: 23517509

Group type: EXPERIMENTAL
Intervention: Implant with dual acid-etched surface and CaP nanoparticles
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control implant with dual acid-etched surface
Number of subjects: 15
Study: 20030701

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking for 30 min at least three times per week) during 4 weeks of external beam radiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard advice (control group)
Number of subjects: 65
Study: 18786565

Group type: EXPERIMENTAL
Intervention: EMG measures of muscle activity in the supposed quiescent limb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement of the involved limb
Number of subjects: 0
Study: 17079556

Group type: EXPERIMENTAL
Intervention: Cleansing with 4.0% chlorhexidine
Number of subjects: 15123

Group type: EXPERIMENTAL
Intervention: Cleansing with soap and water
Number of subjects: 15123

Group type: EXPERIMENTAL
Intervention: Dry cord care
Number of subjects: 15123
Study: 12814055

Group type: EXPERIMENTAL
Intervention: Low-frequency cranial electrostimulation (CES) for 30 minutes a day for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation for 30 minutes a day for 6 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-frequency CES and Sham stimulation
Number of subjects: 16
Study: 10870784

Group type: EXPERIMENTAL
Intervention: Continue exercise (5 or more times weekly)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Reduce exercise (to 3 or fewer sessions of exercise weekly)
Number of subjects: 117
Study: 9234649

Group type: EXPERIMENTAL
Intervention: Yohimbine 5.4 mg t.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yohimbine 10.8 mg t.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yohimbine 16.2 mg t.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yohimbine 21.6 mg b.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yohimbine (all doses)
Number of subjects: 32
Study: 8129993

Group type: EXPERIMENTAL
Intervention: Cyclic mebendazole therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Continuous mebendazole therapy
Number of subjects: 26
Study: 2885298

Group type: EXPERIMENTAL
Intervention: 80 mg of propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31925811

Group type: EXPERIMENTAL
Intervention: EPP EMD + BS
Number of subjects: 30

Group type: COMPARATOR
Intervention: EPP alone
Number of subjects: 30
Study: 29310681

Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 243
Study: 28899891

Group type: EXPERIMENTAL
Intervention: Deep anaesthesia (target BIS value 35)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light anaesthesia (target BIS value 50)
Number of subjects: 0
Study: 25156886

Group type: COMPARATOR
Intervention: APO (doxorubicin, prednisone, vincristine, methotrexate, 6‐mercaptopurine)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: APV (weekly vinblastine)
Number of subjects: 125
Study: 23364472

Group type: EXPERIMENTAL
Intervention: 17DD yellow fever vaccine (17DD‐YFV) at doses from 27,476 IU to 31 IU
Number of subjects: 900
Study: 20521875

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study: 18825157

Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal
Number of subjects: 22
Study: 16892929

Group type: EXPERIMENTAL
Intervention: Eight‐week strength training programme in circuit format executed during school hours, one to three times per week for 40‐60 min per session.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 31
Study: 12678140

Group type: EXPERIMENTAL
Intervention: Bitter melon ingestion (patient treatment group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy without bitter melon (patient control group)
Number of subjects: 60
Study: 10781759

Group type: EXPERIMENTAL
Intervention: Extended-release niacin 375 mg/day to 3,000 mg/day
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1,000 mg/day to 3,000 mg/day
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 8641928

Group type: EXPERIMENTAL
Intervention: G‐CSF administered as required (single injections, n = 21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: G‐CSF administered for at least 3 consecutive days (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: G‐CSF (both groups)
Number of subjects: 41
Study: 7951195

Group type: EXPERIMENTAL
Intervention: Orthosorb pins
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cortical screw (2.7-mm)
Number of subjects: 43
Study: 3303823

Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatinum alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatinum + Methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatinum + 5-Fluoro-uracil
Number of subjects: 0
Study: 29767802

Group type: EXPERIMENTAL
Intervention: START-Play intervention (individualized twice-weekly home intervention for 12 weeks)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: START-Play intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care in early intervention (EI)
Number of subjects: 140
Study: 27026380

Group type: EXPERIMENTAL
Intervention: Spaced learning using emails to teach psychiatric concepts
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no emails)
Number of subjects: 132
Study: 24549105

Group type: EXPERIMENTAL
Intervention: Risperidone or aripiprazole (antipsychotic treatment) for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 35
Study: 23259270

Group type: EXPERIMENTAL
Intervention: Electroacupuncture analgesia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous anesthesia
Number of subjects: 200
Study: 20841532

Group type: EXPERIMENTAL
Intervention: 4-hour course on contextualization
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study: 18507721

Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Obese group (before intervention)
Number of subjects: 21
Study: 15931516

Group type: EXPERIMENTAL
Intervention: DLB, PD, PDD
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study: 12830025

Group type: EXPERIMENTAL
Intervention: Soy-based diet intervention (5 counseling visits, 7 follow-up phone calls, and 12 group meetings)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Soy-based diet intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 220
Study: 11028837

Group type: EXPERIMENTAL
Intervention: Oral tropisetron (5 mg once daily) for 15 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral ondansetron (2 x 8 mg daily) for 15 days
Number of subjects: 20
Study: 8861177

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg twice daily
Number of subjects: 314

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg once daily
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Venlafaxine (increased to 75 mg twice daily after 2 weeks if inadequate response)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg daily
Number of subjects: 314
Study: 1903808

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study: 6348585

Group type: EXPERIMENTAL
Intervention: Pergolide (mean daily dose 3.3 mg, range 0.7 to 7.2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bromocriptine (mean daily dose 42.7 mg, range 5.8 to 87.5 mg)
Number of subjects: 24
Study: 30256229

Group type: EXPERIMENTAL
Intervention: Empowerment program (10 sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 89
Study: 30144034

Group type: EXPERIMENTAL
Intervention: Bilateral Greater Occipital Nerve Block (GONB) with 6 mL of 0.5% bupivacaine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham injection with 1 mL of 0.5% bupivacaine
Number of subjects: 28
Study: 27367987

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.015 mg/kg
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.03 mg/kg
Number of subjects: 315

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 315
Study: 24927291

Group type: EXPERIMENTAL
Intervention: Fertility-related informational intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (alcohol-related informational intervention)
Number of subjects: 69
Study: 21480777

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (40 patients, minimal insertion torque 30 Ncm) with nonoccluding temporary restorations.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Early loaded implants (40 patients) with definitive restoration after 2 months.
Number of subjects: 80
Study: 18435429

Group type: EXPERIMENTAL
Intervention: Early external cephalic version
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late external cephalic version
Number of subjects: 0
Study: 17194733

Group type: EXPERIMENTAL
Intervention: Static magnetic field exposure (0.06-T magnets)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo exposure (identical mattress without magnets)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static magnetic field exposure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 15
Study: 14962235

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 424

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 424
Study: 12150267

Group type: COMPARATOR
Intervention: Traditional therapies appropriate for the patient
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Therapies appropriate for the patient with an oral vertical exercise device
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Home care education and use of the oral exercise device
Number of subjects: 45
Study: 9797793

Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin after 120 mg diltiazem twice a day for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin after 120 mg diltiazem twice a day for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 mg lovastatin
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 mg pravastatin
Number of subjects: 10
Study: 8109598

Group type: EXPERIMENTAL
Intervention: r-HuEPO 300 U/kg on Days 1, 4, 7, and 10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-HuEPO 400 U/kg on Days 1, 5, and 9
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-HuEPO 600 U/kg on Days 1 and 10
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-HuEPO administration
Number of subjects: 24
Study: 2781119

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 214
Study: 327364

Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 128
Study: 31021823

Group type: EXPERIMENTAL
Intervention: Web-based exercise programming system
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control (home exercise prescribed by therapist's usual methods)
Number of subjects: 305
Study: 28882919

Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray (Sativex)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25899519

Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 75
Study: 23578552

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA), daily administration, dosage not specified, duration of therapy not specified.
Number of subjects: 0
Study: 21320196

Group type: EXPERIMENTAL
Intervention: Polyurethane foam in contact with the heel inside plaster cast
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group without polyurethane foam
Number of subjects: 156
Study: 18165591

Group type: EXPERIMENTAL
Intervention: IP meperidine 50 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: IP meperidine 100 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: IP ropivacaine 150 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: IP meperidine 50 mg and ropivacaine 150 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (IP saline with IM meperidine 50 mg)
Number of subjects: 250
Study: 16517311

Group type: EXPERIMENTAL
Intervention: Posterior approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Anteromedial approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Number of subjects: 33
Study: 14626567

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg + Fenofibrate 200 mg (n = 46)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg + Ciprofibrate 100 mg (n = 40)
Number of subjects: 86
Study: 10962119

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal left ventricular mass
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Concentric LV hypertrophy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Eccentric LV hypertrophy
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Normal geometry and mass
Number of subjects: 111
Study: 10181621

Group type: EXPERIMENTAL
Intervention: Continuous quality improvement for adult clinical preventive services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leadership involvement and skill building for change management
Number of subjects: 0
Study: 8417220

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (group 1)
Number of subjects: 199
Study: 2874366

Group type: EXPERIMENTAL
Intervention: Nasal sprays of dexamethasone, tramazoline, and neomycin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nasal sprays of dexamethasone and tramazoline with no antibiotic
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matched placebo (propellant alone)
Number of subjects: 50